| Literature DB >> 31519448 |
Xin-Ran Li1, Yan-Kun Yang2, Rong-Bin Wang3, Fang-Lan An4, Yun-De Zhang4, Jian-Qi Nie1, Hadji Ahamada3, Xiu-Xia Liu5, Chun-Li Liu5, Yu Deng5, Zhong-Hu Bai6, Ye Li7, Xue-Rong Liu8.
Abstract
The anticipated increasing demand for inactivated foot-and-mouth (FMD) disease vaccine calls for its larger production capacity, while development of a large-scale process typically requires high running cost and has very limited experimental throughput at manufacturing scale. Thus, an economic scale-down model of representing a large-scale process becomes necessary and essential. In this study, we used a systematic approach to establish a scale-down model representing a 4000-L culture process for FMD vaccine production by suspension BHK-21 cells. In detail, we firstly compared hydrodynamic properties of three bioreactors (14-L, 800-L and 4000-L) under three different conditions (equivalent mixing time, equivalent shear stress and equivalent volumetric power). We figured out equivalent volumetric power (P/V) potentially as an appropriate scale-down strategy, since it resulted in comparable calculated hydrodynamic parameters among three bioreactors. Next, we used computational fluid dynamics (CFD) simulation to provide more details about hydrodynamic environments inside the bioreactors, which supports the reliability of this scale-down strategy. Finally, we compared cell growth, metabolites, vaccine productivity and product quality attributes during FMD vaccine production by BHK-21 cells and observed very close performances among three bioreactors, which once again demonstrates the robustness of this scale-down model. This scale-down strategy can be applied to study variations and critical quality attributes (CQAs) in the resultant production process based on quality by design (QbD) principles, aiming at further more efficient optimization of vaccine production.Entities:
Keywords: CFD simulation; Cell culture; FMD vaccine; QbD; Scale-down model
Year: 2019 PMID: 31519448 DOI: 10.1016/j.vaccine.2019.09.013
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641